CDKN2A and cancer: Ross et al.24 conducted a similar study involving 29 patients and identified similar therapeutically relevant mutations (eg, TP53, NF1, CDKN2A, MEN1, CTNNB1, and ATM) and reported that approximately 60% of mutated genes in ACC could be targeted with therapies approved in other cancers.